Platform chromatographic purification of AAV gene therapy vectors
Adeno-associated virus (AAV) vectors of various serotypes are considered to have
high potential for gene therapy applications. Currently, manufacturing of AAV vectors faces the challenge of co-production of incompletely formed particles lacking a recombinant viral genome. Empty capsids increase the dose of total AAV administered for efficient transduction and are thought to cause unwanted immunological reactions against the virus.
Removal of empty capsids during manufacturing, as well as analysis of empty/full
AAV particle content is therefore a critical requirement for any AAV production process. This poster demonstrates how CIMmultus™ monolithic columns can be used to purify the AAV and remove empty AAV capsids from the product chromatographically.